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Background: Treatment targeted to achieve reduction in N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) improves outcomes in human congestive heart failure (CHF) patients.
Hypothesis: A pre-specified therapeutic algorithm that increased diuretic or pimobendan usage
will reduce plasma NT-proBNP concentrations in dogs with CHF secondary to myxomatous
mitral valve disease (MMVD).
Animals: Twenty-six dogs with clinically stable CHF secondary to MMVD.
Methods: Prospective, controlled before-and-after study. Dogs were examined up to 3 times
over 21 days. Treatment was prescribed based on NT-proBNP as follows: <1500 pmol/L at
baseline, no treatment adjustment at any point during the study (group 1); ≥1500 pmol/L and
creatinine ≤3.0 mg/dL at baseline or SC visits, treatment escalated according to the algorithm
(group 2); ≥1500 pmol/L at baseline, no treatment adjustment (group 3).
Results: N-terminal pro-B-type natriuretic peptide decreased significantly in group 2 (mean change =
−1736 pmol/L (95% CI, −804 to −2668), P < .001) but not in groups 1 or 3 (623 pmol/L [–631 to
1877 pmol/L], P = .14 and 685 pmol/L [–304 to 1068 pmol/L], P = .46, respectively). Serum BUN
and creatinine did not change significantly between visit 0 and visit 2 in group 1 (median = 23 mg/dL
[range 13-32] versus 19 mg/dL [12-38], P = .72 and 1.15 mg/dL [0.70-1.40] versus 0.95 mg/dL
[0.70-1.10], P = .10, respectively) or group 2 (28 mg/dL [18-87] versus 43.5 mg/dL [21-160],
P = .092 and 1.10 mg/dL [0.90-2.50] versus 1.55 mg/dL [0.90-3.30], P = .062, respectively).
Conclusions and Clinical Importance: Use of this treatment escalation algorithm allows effective
targeting of treatment for CHF in dogs against an objective criterion.
KEYWORDS
biomarker, canine, endocardiosis, treatment
1 | INTRODUCTION
Myxomatous mitral valve disease (MMVD) is the commonest cause of
acquired heart disease in dogs1,2 often resulting in congestive heart
failure (CHF) and eventual cardiac-related death.3,4 Median survival
times after the onset of CHF range widely based on treatment, but
are typically less than 1 year.5–7 Standardized medical treatment rec-
ommendations for dogs with CHF are based on clinical trial results
and consensus opinion7–9; however, decisions regarding dosing and
dose adjustments, especially of diuretic medications, in individual dogs
are made on a case-by-case basis and often rely on subjective criteria
and the clinical acumen of the clinician. It is possible that the applica-
tion of more objective criteria would allow for optimization of medical
treatment in a greater proportional of dogs, potentially improving sur-
vival times.
Abbreviations: ACE, angiotensin converting enzyme; BUN, blood urea nitrogen;
CHF, congestive heart failure; CI, confidence interval; ECG, electrocardiogra-
phy; LA:Ao, ratio of left atrial to aortic root diameter; LVIDd, left ventricular
internal dimension in diastole; LVIDDN, left ventricular internal dimension in
diastole, normalized for body weight; LVIDs, left ventricular internal dimension
in systole; LVIDSN, left ventricular internal dimension in systole, normalized for
body weight; MMVD, myxomatous mitral valve disease; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; VHS, vertebral heart size
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Examples of objective criteria that might be of value in monitoring
the effectiveness of medical treatment for CHF include circulating
biomarkers such as N-terminal proB-type natriuretic peptide (NT-
proBNP). The hypothesis is that CHF treatment administered primarily
to decrease NT-proBNP to a specified level results in decreased mor-
bidity and case fatality. This hypothesis is appealing but controversial.
Recent meta-analyses involving many thousands of human patients
indicated a benefit in morbidity10 and case fatality,11,12 however
important questions involving the optimal NT-proBNP level, nature of
augmented treatment, cost effectiveness, and widespread use of
biomarker-guided treatment remain.13 In dogs with CHF secondary to
MMVD, an observational study indicated that dogs with plasma NT-
proBNP concentrations <965 pmol/L 7–30 days after initial diagnosis
of CHF had significantly longer cardiac survival times than those in
which plasma NT-proBNP concentrations were ≥ 965 pmol/L,14 sug-
gesting the possibility that treatment to specifically lower NT-proBNP
could improve survival. Despite previous trials in humans and observa-
tional data in dogs, whether NT-proBNP concentration can be
reduced by escalation of medical treatment in dogs with CHF has not
been previously reported. The aim of our study was to determine
whether a prespecified therapeutic escalation algorithm would result
in reductions in plasma NT-proBNP concentrations in dogs with stable
CHF secondary to MMVD.
2 | MATERIALS AND METHODS
Our study was approved by the University of Pennsylvania Animal
Use and Care Committee (#805143, #803099) and the University of
Bristol Animal Welfare and Ethical Review Body (VIN/16/055) and
informed owner consent was obtained. Dogs presenting to a teaching
hospital (Matthew J. Ryan Veterinary Hospital of the University
of Pennsylvania, Philadelphia, Pennsylvania) or referral practice
(HeartVets, Gloucestershire, England) with CHF secondary to MMVD
were prospectively recruited. The inclusion criteria for the study were
that a 1st episode of CHF had been diagnosed on the basis of radio-
graphic evidence of pulmonary edema within 21 days before enroll-
ment, clinical signs of CHF were controlled and the dog was receiving
a minimum of furosemide (2 mg/kg/day), enalapril (0.5 mg/kg BID)
and pimobendan (0.25 mg/kg BID). If the original diagnosis of CHF
was made at another hospital thoracic radiographs taken at the time
of diagnosis were made available for review. The exclusion criteria
were more than 1 episode of CHF, treatment with diuretics before
the onset of CHF, systemic hypertension (systolic blood pressure
>170 mm Hg) and the presence of atrial fibrillation or supraventricular
or ventricular tachycardia. Dogs with any other cardiac disease or clin-
ically relevant organ-related or systemic disease were not eligible.
Dogs requiring adjustments in treatment during the study period due
to a deterioration in clinical status (eg, increasing sleeping respiratory
rate, etc.) were withdrawn from the study. Pulmonary hypertension
was not an exclusion criterion. Treatment with an angiotensin con-
verting enzyme (ACE) inhibitor or pimobendan before the onset of
CHF was not an exclusion criterion.
Dogs were examined at baseline (visit 0, ie, up to 21 days after
the initial diagnosis of CHF, at which time dogs were receiving
medications and were clinically stable), and at 2 SC visits, the 1st
between 7 and 10 days (visit 1) and the 2nd between 14 and 20 days
(visit 2) after visit 0 for a maximum of 3 visits (visits 0–2). Clinical sta-
bility was defined as absence of tachypnea or dyspnea and no evi-
dence of pulmonary edema on thoracic radiographs. At visit 0, a
medical history was taken and physical examination, blood sampling,
blood pressure measurement, thoracic radiography, and echocardiog-
raphy were performed. Systolic blood pressure was measured using
Doppler sphygmomanometry using a thoracic limb and the inflatable
cuff closest to 40% of the antebrachial circumference was chosen
(Ultrasonic Doppler Flow Detector, Parks Medical, Aloha, Oregon).
Approximately 3 mL of blood was collected by jugular or cephalic
venipuncture and divided between serum and K-EDTA-treated tubes.
Serum biochemistry was performed by the Veterinary Hospital of the
University of Pennsylvania clinical laboratory. K-EDTA samples were
separated by centrifugation at 1000g for 15 minutes and the resultant
plasma transported at ambient temperature to a reference laboratory
(IDEXX Laboratories Inc, Westbrook, Maine) for analysis of NT-
proBNP concentration using a 2nd generation ELISA assay (Cardiopet
Canine proBNP, IDEXX Laboratories Inc, Westbrook, Maine) that has
been previously validated in dogs.15 The lower and upper limits of
detection of the NT-proBNP assay are 77 and 10 000 pmol/L, respec-
tively.15 Left and right lateral and dorsoventral thoracic radiographic
projections were obtained. Vertebral heart size (VHS) was measured
as previously described by a single observer (MJH).16
Echocardiographic examinations were performed either by a
board-certified cardiologist or a cardiology resident-in-training under
the direct supervision of a board-certified cardiologist. The echocar-
diographic examination was performed using an ultrasound unit (iE33,
Phillips, Andover, Massachusetts) equipped with 3–8 and 1–5 MHz
phased array transducers and electrocardiographic (ECG) monitoring.
Standard imaging planes were digitally stored. Diagnosis of MMVD
was on the basis of characteristic abnormalities of the valve leaflets
(thickening, prolapse or both) and evidence of regurgitant flow across
the valve detected by color flow Doppler. The left atrial to aortic root
ratio (LA : Ao) was measured from the right parasternal short axis
view.17 Left ventricular internal dimension in systole (LVIDs) and dias-
tole (LVIDd) were measured from 2D right parasternal short axis
views. Left ventricular internal dimension in systole was normalized
for body weight (LVIDSN) using the formula: LVIDs/(body weight
[kg])0.315. Left ventricular internal dimension in diastole was normal-
ized for body weight (LVIDDN) using the formula: LVIDd/(body
weight [kg])0.294.18 Dogs were grouped based on whether their NT-
proBNP concentration at visit 0 was < or ≥1500 pmol/L. At visit 0, if
the plasma NT-proBNP concentration was <1500 pmol/L, dogs were
included in group 1 and no dose adjustments were made to the cur-
rent therapeutic regimen and only a physical examination and mea-
surement of circulating markers was performed at the SC visits. If at
visit 0 the plasma NT-proBNP concentration was ≥1500 pmol/L, the
dog was included in group 2. Dogs in group 2 were eligible for prespe-
cified medical treatment escalation on visit 0 or visit 1 if the ser-
um creatinine concentration was <3.0 mg/dL. If creatinine was
≥3.0 mg/dL, data from the dog would be included in the analysis, but
the dog would be ineligible for further treatment escalation. Subse-
quent to recruitment of groups 1 and 2, a third cohort of dogs with
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baseline NT-proBNP ≥1500 pmol/L that received no adjustment in
treatment over a 21 day period was recruited as a control (group 3).
Treatment was escalated according to a prespecified plan as fol-
lows; if the current furosemide dose was <6 mg/kg/day, this dose was
increased by 50%; if the current furosemide dose was ≥6 mg/kg/day,
a combination of hydrochlorothiazide (1 mg/kg q24h) and spironolac-
tone (1 mg/kg q24h; Aldactazide, Pfizer, New York) was added; if the
current dose of furosemide was ≥6 mg/kg/day and the dog was
already receiving hydrochlorothiazide and spironolactone the daily
pimobendan dose was increased by 50%-100%. For dogs assigned to
group 2 at visit 0 or visit 1, all diagnostic tests were repeated at the
next visit. If plasma NT-proBNP measurements were <1500 pmol/L at
visit 1 or 2 the endpoint was reached and the dog did not undergo
any SC evaluation or visits. For dogs in group 3, no dose adjustments
were made to the current therapeutic regimen and plasma NT-
proBNP was measured at visit 0 and again 14–21 days later (equiva-
lent to the timing of visit 2 for groups 1 and 2). Basic demographic
information was collected and radiography and echocardiography
were performed for all dogs in group 3 at visit 0. Only a physical
examination and measurement of NT-proBNP was performed at the
SC visit.
3 | STATISTICAL ANALYSIS
Statistical analysis and sample size calculation was performed using
commercially available software (SPSS 22; IBM, Armonk New York;
PSS: Vanderbilt University, Nashville, Tennessee; GraphPad Prism
7.00, GraphPad Software Inc, La Jolla, California). A value of P < .05
was considered significant. Data were assessed graphically for normal-
ity and by use of the Shapiro Wilk test. Means (± standard deviation)
or medians (ranges) were used to provide descriptive statistics for nor-
mally and non-normally distributed continuous variables, respectively.
Comparisons of continuous variables between groups were performed
using Student's t-tests, Mann-Whitney U tests, one-way ANOVAs
with Tukey's post-hoc tests for multiple comparisons or Kruskal-
Wallis tests with Dunn's post-hoc tests for multiple comparisons, as
appropriate. Comparison of proportions between groups was per-
formed using Chi squared tests.
Repeated measures linear mixed models were used to study the
effect of treatment group (groups 1–3), time and the interaction of
treatment group and time on plasma NT-proBNP concentration and
other variables measured during the study period. The interaction
term (group × time) provides information regarding the significance of
any change over time in the dependent variable for each group. A
compound symmetry covariance structure was assumed between
residuals of the same subject (dog) in the model. The assumption of
normality of model residuals was assessed graphically and by use of
the Shapiro Wilk test.
4 | RESULTS
Twenty-six dogs with CHF secondary to MMVD with a mean age of
11.1 ±2.1 years and a mean body weight of 7.31 ±3.07 kg were
included in the study. Eleven male and 15 female dogs were recruited.
Mixed breeds were most frequently represented (n = 6), followed by
cavalier King Charles spaniels (n = 5), 2 each of Chihuahuas and Toy
Poodles and 1 each of Beagle, Bichon Frisé, Bolognese, Cocker
Spaniel, English Toy Spaniel, Havanese, Maltese terrier, Pomeranian,
Shetland sheepdog, Shih Tzu, and Whippet. All measurements of
plasma NT-proBNP were between the lower and upper limits of
detection of the assay. The owner of 1 dog in group 2 was not compli-
ant with the study protocol and the dog was removed from the study;
no data from this dog are presented. The owners of 4 dogs in group
1 elected not to return for follow up, 2 after visit 0 and 2 after visit 1;
no data from the 2 dogs that did not return for visit 1 are presented,
whereas data from visits 0 and 1 are presented for the 2 dogs that did
not return for visit 2. The reason given for electing not to return was
client inconvenience in all cases and all dogs were reported to be clini-
cally stable. Summary statistics at visit 0 are shown in Table 1. An
overall difference between groups 1 (1170.8 ± 323.7 pmol/L),
2 (3641.0 ± 1505.2 pmol/L), and 3 (2591.0 ± 844.6) was detected at
visit 0 for NT-proBNP (P < .001). Post-hoc analysis demonstrated that
NT-proBNP concentrations were lower in group 1 compared with
both groups 2 and 3 (P < .001 and P = .040, respectively) but did not
differ between groups 2 and 3 (P = .81). An overall difference
between groups 1 (10.8 ± 1.2), 2 (12.1 ± 0.9), and 3 (11.9 ± 0.8) was
detected at visit 0 for VHS (P = .049). Post hoc analysis demonstrated
that VHS measurements were lower in group 1 compared with group
2 (P = .042) but did not differ between groups 1 and 3 or groups
2 and 3 (P = .18 and P = .87, respectively). An overall difference
between groups 1 (1.9 ± 0.3), 2 (2.3 ± 0.4), and 3 (2.6 ± 0.4) was
detected at visit 0 for LA : Ao (P = .011). Post hoc analysis demon-
strated that LA : Ao measurements were lower in group 1 compared
with group 3 (P = .008) but did not differ between groups 1 and 2 or
groups 2 and 3 (P = .19 and P = .13, respectively). An overall differ-
ence between groups 1 (142.7 ± 3.3 mmol/L), 2 (144.5 ± 2.7 mmol/L),
and 3 (148.3 ± 4.3 mmol/L) was detected at visit 0 for Na+ (P = .023).
Post hoc analysis demonstrated that Na+ measurements were lower
in group 1 compared with group 3 (P = .021) but did not differ
between groups 1 and 2 or groups 2 and 3 (P = .52 and P = .088,
respectively).
A flow diagram summarizing the evolution of assignments to
groups 1–3 during the study is depicted in Figure 1. No dog in any of
the 3 groups required adjustments in treatment other than those that
made were in accordance with the study algorithm. At visit 0, 8 dogs
were assigned to group 1 and 12 dogs assigned to group 2. The NT-
proBNP measurement was not reported for 1 dog in group 1 at visit
1 due to an error at the commercial laboratory (the NT-proBNP mea-
surement at visit 2 was available from this dog). Treatment intensifica-
tion at visit 0 consisted of a 50% increase in furosemide dose
(10 dogs) or the addition of hydrochlorothiazide and spironolactone
treatment (1 dog). After intensification of treatment at visit 0, 3 dogs
in group 2 had NT-proBNP concentrations <1500 pmol/L at visit
1. No further treatment intensification was performed in these dogs
and data from visit 2 did not contribute to the statistical analyses.
Treatment intensification at visit 1 consisted of a 50% increase in
furosemide dose (5 dogs), the addition of hydrochlorothiazide and
spironolactone treatment (2 dogs), or a 50% increase in pimobendan
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dose (1 dog). After intensification of treatment at visit 1, 1 of the
remaining 8 dogs in group 2 had NT-proBNP concentrations <1500
pmol/L at visit 2; data from all visits contributed to the statistical ana-
lyses in this dog. One dog in group 2 at visit 2 experienced serum cre-
atinine ≥3.0 mg/dL. This dog was inappetant and appeared nauseous
at the time of visit 2, but improved clinically after temporary suspen-
sion of heart failure medications and cautious fluid treatment. All data
from this dog were included in the statistical analysis. All other dogs
remained clinically stable throughout the study period and no other
adverse events were reported. Subsequently an additional 6 dogs
were recruited to group 3, all of which were examined twice, 14–21
days apart.
A significant difference in the mean change in plasma NT-proBNP
concentrations over the 14–21 days study period was detected
between group 2 (mean change = −1736 pmol/L [95% CI, −804 to
−2,668 pmol/L]), group 1 (mean change = 623 pmol/L, 95% CI, −631
to 1877 pmol/L), and group 3 (mean change = 685 pmol/L, 95% CI,
−304 to 1068 pmol/L; P = .001). Post hoc analysis demonstrated that
the mean change in plasma NT-proBNP concentrations was lower in
groups 1 and 3 compared with group 2 (P = .005 and P = .004,
respectively) but did not differ between groups 1 and 3 (P = .97).
Plasma NT-proBNP decreased significantly over time within group
2 (P < .001) but did not significantly change within group 1 or group
3 (P = .14 and .46, respectively).
No significant change in serum BUN concentrations was detected
between visit 0 (median = 23 mg/dL, range 13–32) and visit 2 (median =
19 mg/dL, range 12–38) for group 1 (P = .72). No significant change in
serum BUN concentrations was detected between visit 0 (median =
28 mg/dL, range 18–87) and visit 2 (median = 43.5 mg/dL, range
21–160) for group 2 (P = .092). No significant change in serum
creatinine concentrations was detected between visit 0 (median =
1.15 mg/dL, range 0.70-1.40) and visit 2 (median = 0.95 mg/dL, range
0.70-1.10) for group 1 (P = .10). No significant change in serum
creatinine concentrations was detected between visit 0 (median =
1.10 mg/dL, range 0.90-2.50) and visit 2 (median = 1.55 mg/dL, range
0.90-3.30) for group 2 (P = .062). Plots of individual dogs’ plasma
NT-proBNP and serum BUN and creatinine concentrations throughout
the study period are shown in Figures 2–4, respectively.
TABLE 1 Baseline signalment, basic echocardiographic data, treatments and serum and plasma biochemistry measurements of 23 dogs that had
at least 1 recheck visit
Variable Group 1 (n = 6) Group 2 (n = 11) Group 3 (n = 6) P value (between groups)
Age (years) 11.2 ± 0.6 11.0 ± 2.3 8.9 ± 2.8 .75
Sex (no. male/no. female) 3/3 6/5 2/4 .70
Body weight (kg) 6.5 ± 1.1 8.1 ± 3.8 7.8 ± 2.7 .60
Time from onset of CHF (days) 10 (6–23) 10 (7–19) 8 (1–23) .80
Murmur intensity 5 (4–5) 4 (3–5) 4 (4–5) .098
Heart rate (bpm) 141.0 ± 22.7 141.5 ± 26.0 144.3 ± 23.7 .97
Systolic blood pressure (mm Hg) 132.3 ± 30.7 131.0 ± 16.9 123.2 ± 26.2 .76
Furosemide (mg/kg/day) 3.7 (3.3–4.9 3.3 (1.9 – 11.0) 3.5 (3.3–4.1) .56
ACE inhibitor (mg/kg/day) 1.1 ± 0.2 1.0 ± 0.3 0.7 ± 0.4 .058
Pimobendan (mg/kg/day) 0.5 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 .14
VHS 10.8 ± 1.2 12.1 ± 0.9 11.9 ± 0.8 .049
Group 1 versus 2, P = .042
LA : Ao 1.9 ± 0.3 2.3 ± 0.4 2.6 ± 0.4 .011
Group 1 versus 3, P = .008
LVIDDN (cm/kg0.294) 1.90 (1.72-2.14) 2.15 (1.60-2.92) 2.25 (1.70-2.41) .21
LVIDSN (cm/kg0.315) 0.84 (0.59-1.10) 1.03 (0.61-2.12) 1.20 (0.69-1.43) .16
Fractional shortening (%) 55.3 ± 7.1 48.9 ± 11.0 44.7 ± 8.3 .17
E wave velocity (m/s) 1.22 (1.12-1.85) 1.33 (1.11-2.00) 1.42 (0.79-1.62) .57
Tricuspid regurgitation velocity (m/s) 3.1 ± 0.5 3.2 ± 0.4 2.6 ± 1.6 .62
NT-proBNP (pmol/L) 1170.8 ± 323.7 3641.0 ± 1505.2 2591.0 ± 844.6 <.001
Group 1 versus 2, P < .001
Group 1 versus 3, P = .040
BUN (mg/dL) 28 (13–32) 28 (16–87) 28.5 (23–94) .58
Creatinine (mg/dL) 1.0 (0.5-1.4) 1.0 (0.9-2.5) 1.2 (0.9-1.7) .70
Na+ (mmol/L) 142.7 ± 3.3 144.5 ± 2.7 148.3 ± 4.3 .023
Group 1 versus 3, P = .021
K+ (mmol/L) 4.5 ± 0.5 4.7 ± 0.8 4.6 ± 0.6 .91
Normally distributed data are displayed as mean ± standard deviation. Non-normally distributed data are displayed as median (range).
Abbreviations: ACE, angiotensin converting enzyme; BUN, blood urea nitrogen; K+, potassium; LA : Ao, left atrial to aortic ratio; LVIDDN, left ven-
tricular internal dimension in diastole, normalized for body weight; LVISDN, left ventricular internal dimension in systole, normalized for body
weight; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Na+, sodium.
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5 | DISCUSSION
Our study demonstrates that application of a prespecified treatment
escalation algorithm in dogs with recent history and treatment of 1st
time CHF secondary to MMVD results in a decrease in plasma NT-
proBNP concentrations. An important feature of our study is that
dogs in all 3 groups were clinically stable after routine treatment of
their recent CHF. Thus, the decision to escalate treatment was made
on their NT-proBNP concentration rather than on the presence
(or absence) of clinical signs. In this way, NT-proBNP or any biomarker
directed treatment represents a treatment strategy different than
what is typically performed.
The plasma NT-proBNP threshold of 1500 pmol/L was chosen
on the basis of the results from a previous study, which reported
that dogs with MMVD in which NT-proBNP was < 965 pmol/L after
treatment for CHF survived significantly longer than those in which
NT-proBNP remained ≥ 965 pmol/L.14 In this earlier study, NT-
proBNP was measured using the 1st-generation version of the
ELISA, whereas measurements in our study were obtained using the
2nd-generation version of the assay, which is known to yield higher
values compared with the 1st generation assay.19 A scaling factor of
1.5 to achieve the threshold of 1500 pmol/L was derived by com-
paring cut-offs for differentiating cardiac from noncardiac causes of
respiratory distress using the 1st- and 2nd-generation versions of
the assay.19,20 In the aforementioned previous study, NT-proBNP
concentration at time of active CHF was not found to be predictive
of survival, suggesting that the NT-proBNP concentration achieved
after resolution of CHF signs and during SC maintenance treatment
was important. It remains unknown whether the achieved decrease
in plasma NT-proBNP concentrations in our study would improve
survival or reduce risk of SC episodes of CHF, and future random-
ized study of the effects of NT-proBNP lowering on morbidity and
case fatality is appealing.
Studies in human patients have used a variety of treatment esca-
lation strategies including introduction or uptitration of loop and thia-
zide diuretics, ACE inhibitors, spironolactone, digoxin, beta-blockers,
and inodilators. In some studies, a prespecified treatment escalation
algorithm was followed21,22 while in other studies the attending clini-
cian was instructed to escalate treatment according to their individual
clinical judgment.23–25 Our study used an empirical prespecified treat-
ment escalation strategy that, included increasing existing doses of
furosemide followed by introduction of thiazide diuretics and spirono-
lactone, similar to the algorithms described in the aforementioned
human studies. If uptitration of diuretics did not result in a reduction
of the plasma NT-proBNP concentration, an increased dose of pimo-
bendan was given. While these treatment options are amongst those
available for dogs that require more aggressive treatment,8 the rela-
tive effect of alternative treatment strategies, such as those involving
ACE inhibitors, digoxin, etc, requires further study.
Serum BUN and creatinine concentrations did not significantly
increase with treatment escalation in our study. However, one dog
did become clinically azotemic and so, as with any change in diuretic
administration, careful monitoring of renal values is important during
escalation of treatment.
FIGURE 1 Flow diagram of the progress through the phases of the study for groups 1–3. Dogs presenting with plasma NT-proBNP ≥ 1500
pmol/L at the time of initial recruitment were assigned to group 2; an additional 6 dogs with plasma NT-proBNP ≥ 1500 pmol/L were subse-
quently recruited to group 3
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The study has a number of limitations. At visit 0, dogs in group
2 had higher VHS versus dogs in group 1, and dogs in group 3 had
higher LA : Ao vs. dogs in group 1, as might be expected for dogs with
higher plasma NT-proBNP concentrations, however, indices of heart
size were not significantly different between the 2 groups with high
NT-proBNP concentrations at baseline (ie, group 2 versus 3). Treat-
ment was only escalated in dogs with NT-proBNP concentrations
≥1500 pmol/L and the effect of escalation of treatment in dogs with
different concentrations remains unknown. The patient sample was
small and restricted to dogs with recent onset and treatment of CHF,
which limits the generalizability of the study findings. The decision to
escalate treatment in dogs with NT-proBNP ≥1500 pmol/L was not
made on the basis of a randomization protocol, but according to the
time of presentation, as dogs presenting at the time of initial recruit-
ment were all assigned to group 2 and dogs in group 3 was subse-
quently recruited as a convenience sample. Consequently, the dogs in
group 3 were recruited at a different time point to dogs in groups
1 and 2 which might have influenced the results. Drop-out was rela-
tively high as some owners found it difficult to comply with the fre-
quent study rechecks, and the need for additional rechecks in an
apparently stable dog could decrease the practicality of biomarker-
guided treatment. All dogs were receiving diuretic treatment, and so
renal concentrating ability could not be assessed; renal function was
therefore estimated on the basis of BUN and creatinine concentra-
tions alone and these elevations might reflect renal or prerenal causes.
Finally, dogs of a variety of breeds were recruited and the groups
were not balanced according to breed; this might have influenced the
results of the study, as breed-specific differences in circulating NT-
proBNP concentrations in healthy dogs have been reported.26
In conclusion, a prespecified treatment escalation algorithm
reduces plasma NT-proBNP concentrations in dogs with clinically
FIGURE 2 Plots of individual dogs’ plasma NT-proBNP concentra-
tions throughout the study period for (A) group 1, (B) group 2, and
(C) group 3. The dotted line in each case represents the 1500 pmol/L
cut-off
FIGURE 3 Plots of individual dogs’ serum BUN concentrations
throughout the study period for (A) group 1 and (B) group 2. The
dotted line in each case represents the upper limit of the laboratory
reference interval (30 mg/dL)
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stable CHF secondary to MMVD. Careful monitoring of renal function
is recommended during escalation of treatment for CHF. Further ran-
domized studies involving larger numbers of dogs are warranted to
assess the effect of lowering NT-proBNP on morbidity and case
fatality.
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